Treating acute kidney injury (AKI) represents an important unmet medical need both in terms of the seriousness of this medical problem and the number of patients. There is also a large untapped market opportunity in treating AKI. Over the years, there has been much effort in search of therapeutics with minimal success. However, over the same time period, new understanding of the underlying pathobiology and molecular mechanisms of kidney injury have undoubtedly helped the search for new therapeutics. Along this line, carbon monoxide (CO) has emerged as a promising therapeutic agent because of its demonstrated cytoprotective, and immunomodulatory effects. CO has also been shown to sensitize cancer, but not normal cells, to chemotherapy. This is particularly important in treating cisplatin‐induced AKI, a common clinical problem that develops in patients receiving cisplatin therapies for a number of different solid organ malignancies. This review will examine and make the case that CO be developed into a therapeutic agent against AKI.

中文翻译：

---

一氧化碳：一种治疗急性肾损伤的新兴疗法。

就该医疗问题的严重性和患者数量而言，治疗急性肾损伤 (AKI) 代表了一项重要的未满足的医疗需求。在治疗 AKI 方面也存在巨大的未开发市场机会。多年来，人们一直在努力寻找治疗方法，但收效甚微。然而，在同一时期，对肾损伤潜在病理生物学和分子机制的新认识无疑有助于寻找新的治疗方法。沿着这条线，一氧化碳 (CO) 已成为一种有前途的治疗剂，因为它具有细胞保护和免疫调节作用。一氧化碳也被证明会使癌症对化疗敏感，但不会使正常细胞对化疗敏感。这对于治疗顺铂诱导的 AKI 尤为重要，这是在接受顺铂治疗的患者中出现的常见临床问题，用于治疗多种不同的实体器官恶性肿瘤。本次审查将审查并说明将 CO 开发为 AKI 治疗剂的案例。